Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
Cervarix is a recombinant cervical cancer vaccine recently developed by GlaxoSmithKline Biologicals (Rixensart, Belgium). This vaccine is a prophylactic AS04 adjuvanted bivalent L1 virus-like-particle vaccine against human papillomavirus types 16 and 18, which together account for approximately 70% of cervical cancers worldwide. An interim analysis of a large, multicenter, Phase III trial being conducted by the Papilloma Trial against Cancer In young Adults (PATRICIA) study group to assess the efficacy of this vaccine was recently published in The Lancet. The purpose of this review is to summarize PATRICIA, with a specific focus on the results of the interim analysis, and discuss the impact and implications of the findings.
Frederick
Peter J
PJ
University of Alabama at Birmingham, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, 619 19th Street South, OHB 538, Birmingham, AL 35249-7333, USA. pfred@uab.edu
Huh
Warner K
WK
D000293:Adolescent; D000328:Adult; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000517:prevention & control* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000209:etiology / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18